VistaGen Therapeutics, Inc.·4

Jan 3, 4:10 PM ET

Singh Shawn 4

4 · VistaGen Therapeutics, Inc. · Filed Jan 3, 2023

Insider Transaction Report

Form 4
Period: 2022-12-30
Singh Shawn
DirectorCHIEF EXECUTIVE OFFICER
Transactions
  • Award

    Common Stock

    2022-12-30$0.09/sh+5,000$438158,998 total
Holdings
  • Common Stock

    (indirect: By Trust)
    626,234
Footnotes (1)
  • [F1]Shares purchased under the Vistagen Therapeutics, Inc. 2019 Employee Stock Purchase Plan ("ESPP").

Documents

1 file
  • 4
    form4-01032023_090116.xmlPrimary